Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients (55 page)

51
You might also enjoy some of the books written by retired drug reps, such as: Reidy J. Hard Sell: The Evolution of a Viagra Salesman. 1st ed. Andrews McMeel Publishing; 2005.

52
Rockoff JD. Drug Reps Soften Their Sales Pitches. Wall Street Journal [Internet]. 2012 Jan 10 [cited 2012 Mar 22]; Available from: http://online.wsj.com/article/ SB10001424052970204331304577142763014776148.html

53
Fugh-Berman A, Ahari S. Following the Script: How Drug Reps Make Friends and Influence Doctors. PLoS Med. 2007 Apr;4(4).

54
Soyk, C., B. Pfefferkorn, P. McBride, and R. Rieselbach. 2010. Medical student exposure to and attitudes about pharmaceutical companies. World Medical Journal 109: 142–148.

55
Fischer MA, Keough ME, Baril JL, Saccoccio L, Mazor KM, Ladd E, et al. Prescribers and Pharmaceutical Representatives: Why Are We Still Meeting? J Gen Intern Med. 2009 Jul;24(7):795–801.

56
Morgan MA, Dana J, Loewenstein G, Zinberg S, Schulkin J. Interactions of doctors with the pharmaceutical industry. J Med Ethics. 2006 Oct;32(10):559–63.

57
B Hodges, ‘Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks,’
CMAJ: Canadian Medical Association Journal = Journal De l’Association Medicale Canadienne
153, no. 5 (September 1, 1995): 553–559.

58
Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians’ Prescribing: A Systematic Review. PLoS Med. 2010 Oct 19;7(10):e1000352.

59
MM Chren and CS Landefeld, ‘Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary,’
JAMA: The Journal of the American Medical Association
271, no. 9 (March 2, 1994): 684–689.

60
Ladd EC, Mahoney DF, Emani S. ‘Under the radar’: nurse practitioner prescribers and pharmaceutical industry promotions. Am J Manag Care. 2010;16(12):e358–362.

61
Zipkin DA, Steinman MA. Interactions Between Pharmaceutical Representatives and Doctors in Training. J Gen Intern Med. 2005 Aug;20(8):777–86.

62
Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturers’ employees present grand rounds, what do residents remember? Acad Med. 1996 Jan;71(1):86–8.

63
Wazana A. Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift? JAMA. 2000 Jan 19;283(3):373–80.

64
Lurie N, Rich EC, Simpson DE, Meyer J, Schiedermayer DL, Goodman JL, et al. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. 1990 Jun;5(3):240–3.

65
Fugh-Berman A, Ahari S. Following the Script: How Drug Reps Make Friends and Influence Doctors. PLoS Med. 2007 Apr;4(4).

66
Ibid.

67
Sismondo S. How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science & Medicine. 2008;66(9):1909–14.

68
Completed Cases – PMCPA Website [Internet]. [cited 2012 Mar 26]. Available from: http://www.pmcpa.org.uk/? q=node/868

69
Completed Cases – PMCPA Website [Internet]. [cited 2012 Mar 26]. Available from: http://www.pmcpa.org.uk/?q=node/883

70
Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992 Jul;102(1):270–3.

71
Steinbrook R. For sale: physicians’ prescribing data. N. Engl. J. Med. 2006 Jun 29;354(26):2745–7.

72
Physician Data Restriction Program (PDRP) [Internet]. [cited 2012 Mar 22]. Available from: http://www.ama-assn.org/ama/ pub/about-ama/physician-data-resources/ama-database-licensing/amas-physician-data-restriction-program.page

73
Outterson K. Higher First Amendment Hurdles for Public Health Regulation. New England Journal of Medicine. 2011 Aug 18;365(7):e13.

74
Zipkin DA, Steinman MA. Interactions Between Pharmaceutical Representatives and Doctors in Training. J Gen Intern Med. 2005 Aug;20(8):777–86.

75
Wislar JS, Flanagin A, Fontanarosa PB, DeAngelis CD. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011 Oct 25;343(oct25 1):d6128–d6128.

76
Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Ghost Authorship in Industry-Initiated Randomised Trials. PLoS Med. 2007 Jan 16;4(1):e19.

77
‘Ghost writing in the medical literature’ 111th Congress, United States Senate Committee on Finance Sen. Charles E. Grassley, 2010. [cited 2012 Mar 24]. Available from: http://www.grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf

78
Richard Horton PI 108, House of Commons – Health – Minutes of Evidence [Internet]. [cited 2012 Mar 24]. Available from: http://www.publications.parliament.uk/pa/cm200405/ cmselect/cmhealth/42/4121604.htm

79
Galanter M, Galanter M, Felstiner WLF, Friedman LM, Girth M, Goldstein P, et al. Why the haves come out ahead: Speculations on the limits of legal change. Law Society Review. 1974;9:95–169.

80
Lilly ‘Ghostwrote’ Articles to Market Drug, Files Say (Update2) – Bloomberg [Internet]. [cited 2012 Mar 24]. Available from: http://www.bloomberg.com/apps/news?pid=newsarchive&sid= a6yFu_t9NyTY

81
http://www.psychiatrynorthwest.co.uk/general_adult_ psychiatry/spr_posts/salford-haddad/index.html

82
Medical Press Pre-Launch Feature Outline, Zyprexa MDL 1596, confidential subject to protection order ZY200187608. http://zyprexalitigationdocuments.com/per cent5Cdocuments per cent5CConfidentiality-Challenge per cent5CDocs-challenged-in-10-3-list per cent5C145-ZY200187608-7614.pdf

83
Drug Industry Document Archive [Internet]. [cited 2012 Mar 24]. Available from: http://dida.library.ucsf.edu/

84
Drug Industry Document Archive – Search Results [Internet]. [cited 2012 Mar 24]. Available from: http://dida.library.ucsf. edu/tid/anu38h10

85
Ibid.

86
Ross, J.S., K.P. Hill, D.S. Egilman, and H.M. Krumholz. 2008. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. Journal of the American Medical Association 299: 1800–1812.

87
POGO Letter to NIH on Ghostwriting Academics [Internet]. Project On Government Oversight. [cited 2012 Mar 24]. Available from: http://www.pogo.org/pogo-files/letters/public-health/ph-iis-20101129.html

88
http://www.nytimes.com/2010/11/30/business/30drug.html

89
http://pogoblog.typepad.com/pogo/gw-attachment-e.html

90
Lacasse JR, Leo J. Ghostwriting at Elite Academic Medical Centers in the United States. PLoS Med. 2010 Feb 2;7(2):e1000230.

91
Matheson A. How Industry Uses the ICMJE Guidelines to Manipulate Authorship – And How They Should Be Revised. PLoS Med. 2011;8(8):e1001072.

92
Dyer O. Journal rejects article after objections from marketing department. BMJ. 2004 Jan 31;328(7434):244–b–244.

93
Fugh-Berman A, Alladin K, Chow J. Advertising in Medical Journals: Should Current Practices Change? PLoS Med. 2006 May 2;3(6):e130.

94
Becker A, Dörter F, Eckhardt K, Viniol A, Baum E, Kochen MM, et al. The association between a journal’s source of revenue and the drug recommendations made in the articles it publishes. CMAJ. 2011 Feb 28 Available from: http://www.cmaj.ca/content/early/2011/02/28/cmaj.100951

95
Smith R. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med. 2005 May 17;2(5):e138.

96
AUTH/2424/8/11 and AUTH/2425/8/11 – General Practitioner v Boehringer Ingelheim and Lilly. Available from: http://www.pmcpa.org.uk/?q=node/998.

97
Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ramagopalan SV. High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ. 2012 Jun 28;344(jun28 1):e4212–e4212.

98
Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ. 2009 Feb 12;338(feb12_2):b354.

99
http://classic.the-scientist.com/blog/display/55679/

100
http://elsevier.com/wps/find/authored -_newsitem.cws_home/companynews05_01203

101
Bowman MA. The impact of drug company funding on the content of continuing medical education. Möbius: A Journal for Continuing Education Professionals in Health Sciences. 1986 Jan 1;6(1):66–9.

102
Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education in the Health Professions. 1988 Jan 1;8(1):13–20.

103
The Carlat Psychiatry Blog: PRMS [Internet]. [cited 2012 Mar 31]. Available from: http://carlatpsychiatry.blogspot.co.uk/ search/label/PRMS

104
Stephan Sahm, ‘Of mugs, meals and more: the intricate relations between physicians and the medical industry.,’
Medicine, health care, and philosophy
(2011).

105
Avorn J, Choudhry NK. Funding for Medical Education: Maintaining a Healthy Separation From Industry. Circulation. 2010 May 25;121(20):2228–34.

106
L. Garattini et al., ‘Continuing Medical Education in six European countries: A comparative analysis,’
Health policy
94, no. 3 (2010): 246–254.

107
Eckardt VF. Complimentary journeys to the World Congress of Gastroenterology – an inquiry of potential sponsors and beneficiaries. Z Gastroenterol. 2000 Jan;38(1):7–11.

108
http://www.pmlive.com/find_an_article/allarticles/categories/General/2011/november_2011/features/cme_continuing_medic al_education_change

109
US Senate Committee on Finance. Committee Staff Report to the Chairman and Ranking Member: Use of Educational Grants by Pharmaceutical Manufacturers. Washington, DC: Government Printing Office; 2007.

110
Hensley S, Martinez B. To sell their drugs, companies increasingly rely on doctors. Wall St J (East Ed). 2005 Jul 15;A1,A2.

111
Tabas JA, Boscardin C, Jacobsen DM, Steinman MA, Volberding PA, Baron RB. Clinician Attitudes About Commercial Support of Continuing Medical Education: Results of a Detailed Survey. Arch Intern Med. 2011 May 9;171(9):840–6.

112
Amy T Wang et al., ‘Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review,’
BMJ
340, no. 18 (March 18, 2010): c1344.

113
Rothman KJ, Evans S (2005) Extra scrutiny for industry funded trials. BMJ 331: 1350–1351

114
Wager E, Mhaskar R, Warburton S, Djulbegovic B (2010) JAMA Published Fewer Industry-Funded Studies after Introducing a Requirement for Independent Statistical Analysis. PLoS ONE 5(10): e13591. doi:10.1371/journal.pone.0013591

115
Chalmers TC, Frank CS, Reitman D. Minimizing the Three Stages of Publication Bias. JAMA. 1990 Mar 9;263(10):1392–5.

116
Samena Chaudhry et al., ‘Does declaration of competing interests affect readers’ perceptions? A randomised trial,’ BMJ 325, no. 7377 (December 14, 2002): 1391–1392. (below).

117
Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. JAMA. 2011;305(10):1008–1017. doi: 10.1001/jama.2011.257

118
Loewenstein G, Sah S, Cain DM. The Unintended Consequences of Conflict of Interest Disclosure. JAMA. 2012 Feb 15;307(7):669–70.

119
Cain, D. M., Loewenstein, G., & Moore, D. A. (2005). The dirt on coming clean: perverse effects of disclosing conflicts of interest. Journal of Legal Issues, 34, 1e25.

120
Campbell EG, Weissman JS, Ehringhaus S
et al
. Institutional academic industry relationships.
JAMA
2007;298:1779–86.

121
http://www.propublica.org/series/dollars-for-docs

122
http://www.propublica.org/article/doctors-dine-on-drug-companies-dime

123
http://www.propublica.org/article/dollars-for-docs-sparks-policy-rewrite-at-colorado-teaching-hospitals

124
http://www.propublica.org/article/medical-schools-plug-holes-in-conflict-of-interest-policies

125
http://www.propublica.org/article/dollars-to-doctors-physician-disciplinary-records/single

126
http://www.propublica.org/article/drug-companies-reduce-payments-to-doctors-as-scrutiny-mounts